Hondeghem L M
Hondeghem Pharmaceutical Consulting N.V., Oostende, Belgium.
J Cardiovasc Electrophysiol. 1994 Aug;5(8):711-21. doi: 10.1111/j.1540-8167.1994.tb01193.x.
Most antiarrhythmic agents were discovered accidentally. In the last decade, the understanding of the mechanisms of action of agents with electrophysiologic activity has progressed greatly. As a result, it was possible to compute, before the CAST trial, that the agents selected for the trial would not be effective against tachycardias and that the drugs would be unsafe. Extension of these computations to existing Class I agents indicated that they were all poor suppressors of ventricular tachycardia. Furthermore, a Class I agent with an optimal electrophysiologic profile still computes to be a two-edged sword, possessing both antiarrhythmic and proarrhythmic properties. Fortunately, it is possible to conceive of drug profiles that would be purer antiarrhythmic agents. For example, a drug that only upon the development of a tachycardia lengthens action potential duration in a use-dependent manner until the refractory period exceeds the tachycardia cycle length will render continuation of the tachycardia impossible. Recognition of chemicals that have Class IIIa properties with the appropriate kinetics is a challenging task. However, today's microprocessors have become powerful enough to characterize the Class III kinetics. A system that fully automatically screens for effective antiarrhythmic agents is described. It is expected that chemicals selected for optimal basic electrophysiologic properties will yield safer and more effective antiarrhythmic agents.
大多数抗心律失常药物都是偶然发现的。在过去十年中,对具有电生理活性药物作用机制的理解有了很大进展。因此,在CAST试验之前就有可能推断出,该试验所选药物对心动过速无效且不安全。将这些推断应用于现有的I类药物表明,它们对室性心动过速的抑制效果都很差。此外,具有最佳电生理特性的I类药物经计算仍是一把双刃剑,兼具抗心律失常和促心律失常特性。幸运的是,可以设想出更纯粹的抗心律失常药物特性。例如,一种仅在心动过速发生时以使用依赖方式延长动作电位时程直至不应期超过心动过速周期长度的药物,将使心动过速无法持续。识别具有适当动力学特性的IIIa类化学物质是一项具有挑战性的任务。然而,如今的微处理器已经强大到足以表征III类动力学特性。本文描述了一种能全自动筛选有效抗心律失常药物的系统。预计选择具有最佳基本电生理特性的化学物质将产生更安全、更有效的抗心律失常药物。